Compare · PRCT vs WST
PRCT vs WST
Side-by-side comparison of PROCEPT BioRobotics Corporation (PRCT) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PRCT and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $23.38B, about 14.1x PRCT ($1.66B).
- Over the past year, PRCT is down 53.2% and WST is up 47.6% - WST leads by 100.8 points.
- PRCT has been more active in the news (16 items in the past 4 weeks vs 5 for WST).
- PRCT has more recent analyst coverage (25 ratings vs 17 for WST).
- Company
- PROCEPT BioRobotics Corporation
- West Pharmaceutical Services Inc.
- Price
- $29.11+1.11%
- $330.81-1.15%
- Market cap
- $1.66B
- $23.38B
- 1M return
- +9.95%
- +2.66%
- 1Y return
- -53.15%
- +47.63%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 16
- 5
- Recent ratings
- 25
- 17
PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest PRCT
- PROCEPT BioRobotics downgraded by Leerink Partners with a new price target
- Director Desai Antal Rohit was granted 3,315 shares, increasing direct ownership by 9% to 38,467 units (SEC Form 4)
- Director Dodrill Amy M. was granted 3,315 shares, increasing direct ownership by 43% to 10,941 units (SEC Form 4)
- Director Garrett Mary was granted 3,315 shares, increasing direct ownership by 23% to 17,700 units (SEC Form 4)
- Director Harris Taylor C. was granted 3,315 shares, increasing direct ownership by 3% to 102,491 units (SEC Form 4)
- Director Little Elisabeth Sandoval was granted 3,315 shares, increasing direct ownership by 26% to 15,876 units (SEC Form 4)
- Director Moll Frederic H was granted 3,315 shares, increasing direct ownership by 0.38% to 866,474 units (SEC Form 4)
- Director Prescott Thomas M was granted 3,315 shares, increasing direct ownership by 85% to 7,211 units (SEC Form 4)
- Director Puckett Dan was granted 3,315 shares, increasing direct ownership by 61% to 8,791 units (SEC Form 4)
- PROCEPT BioRobotics Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
Latest WST
- West Pharm upgraded by Barclays with a new price target
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SVP, Proprietary Segment Campbell Shane Alden covered exercise/tax liability with 219 shares and converted options into 770 shares, increasing direct ownership by 881% to 613 units (SEC Form 4)
- SEC Form SD filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Pucci Paolo was granted 791 shares, increasing direct ownership by 7% to 11,854 units (SEC Form 4)
- Director Michels Douglas A was granted 791 shares, increasing direct ownership by 2% to 46,496 units (SEC Form 4)